Mural Oncology plc (MURA) 10-Year Financial Performance & Capital Metrics

MURA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutMural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.Show more

Revenue $0
EBITDA -$135M +29.8%
Net Income -$129M +38.0%
EPS (Diluted) -7.58 +39.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -63.57% +62.9%
ROIC -505.39% +90.1%
Debt/Equity 0.06 +0.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM24.18%

ROCE

10Y Avg-3751.32%

5Y Avg-3751.32%

3Y Avg-1864.07%

Latest-66.48%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	1.47M	0	2.57M	3.51M
COGS % of Revenue	-	-	-	-
Gross Profit+	-1.47M	0	-2.57M	-3.51M
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	1%	-	-0.37%
Operating Expenses+	173.89M	184.92M	192.07M	134.75M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	15.55M	17.73M	30.04M	27.6M
SG&A % of Revenue	-	-	-	-
Research & Development	159.82M	167.19M	162.03M	110.67M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	-1.47M	0	0	-3.51M
Operating Income+	-175.37M	-184.92M	-194.64M	-138.26M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-0.05%	-0.05%	0.29%
EBITDA+	-173.89M	-183.38M	-192.07M	-134.75M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-0.05%	-0.05%	0.3%
D&A (Non-Cash Add-back)	1.47M	1.54M	2.57M	3.51M
EBIT	-175.37M	-184.92M	-195.29M	-128.51M
Net Interest Income+	0	0	0	9.75M
Interest Income	0	0	0	9.75M
Interest Expense	0	0	0	0
Other Income/Expense	0	0	-649K	9.75M
Pretax Income+	-175.37M	-184.92M	-195.29M	-128.51M
Pretax Margin %	-	-	-	-
Income Tax+	68K	4.88M	12.16M	0
Effective Tax Rate %	1%	1.03%	1.06%	1%
Net Income+	-175.43M	-189.81M	-207.45M	-128.51M
Net Margin %	-	-	-	-
Net Income Growth %	-	-0.08%	-0.09%	0.38%
Net Income (Continuing)	-175.43M	-189.81M	-207.45M	-128.51M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-10.51	-11.37	-12.43	-7.58
EPS Growth %	-	-0.08%	-0.09%	0.39%
EPS (Basic)	-10.51	-11.37	-12.43	-7.58
Diluted Shares Outstanding	16.69M	16.69M	16.69M	16.95M
Basic Shares Outstanding	16.69M	16.69M	16.69M	16.95M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	4.24M	4.82M	277.34M	152.92M
Cash & Short-Term Investments	0	0	270.85M	144.38M
Cash Only	0	0	270.85M	115.46M
Short-Term Investments	0	0	0	28.92M
Accounts Receivable	0	0	5.55M	51K
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	2.04M	1.83M	787K	805K
Total Non-Current Assets+	30.87M	28.93M	24.41M	16.48M
Property, Plant & Equipment	30.87M	28.93M	24.15M	14.5M
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	258K	1.98M
Total Assets+	35.11M	33.75M	301.75M	169.39M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.04%	7.94%	-0.44%
Total Current Liabilities+	33.25M	41.56M	29.02M	26.2M
Accounts Payable	10.59M	2.97M	5.97M	2.06M
Days Payables Outstanding	2.62K	-	849.3	213.68
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	6.3M	7.1M	5.86M	8.16M
Current Ratio	0.13x	0.12x	9.56x	5.84x
Quick Ratio	0.13x	0.12x	9.56x	5.84x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	19.74M	13.85M	8.91M	2.7M
Long-Term Debt	0	0	0	0
Capital Lease Obligations	19.39M	13.54M	8.91M	2.46M
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	356K	304K	0	235K
Total Liabilities	52.99M	55.41M	37.93M	28.89M
Total Debt+	25.31M	19.39M	15.01M	8.02M
Net Debt	25.31M	19.39M	-255.84M	-107.44M
Debt / Equity	-	-	0.06x	0.06x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-	-	-
Total Equity+	-17.88M	-21.66M	263.82M	140.5M
Equity Growth %	-	-0.21%	13.18%	-0.47%
Book Value per Share	-1.07	-1.30	15.81	8.29
Total Shareholders' Equity	-17.88M	-21.66M	263.82M	140.5M
Common Stock	0	0	167K	171K
Retained Earnings	0	0	-30.86M	-159.37M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-156.67M	-168.59M	-194.25M	-128.54M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-0.08%	-0.15%	0.34%
Net Income	-175.43M	-189.81M	-207.45M	-128.51M
Depreciation & Amortization	1.47M	1.54M	2.57M	3.51M
Stock-Based Compensation	11.5M	11.93M	24.11M	5.08M
Deferred Taxes	-14.45M	-15.01M	0	0
Other Non-Cash Items	14.45M	15.01M	0	-2.58M
Working Capital Changes	5.79M	7.75M	-13.48M	-6.05M
Change in Receivables	0	0	0	5.5M
Change in Inventory	0	0	0	0
Change in Payables	0	0	0	0
Cash from Investing+	-4.38M	-5.51M	-3.45M	-25.33M
Capital Expenditures	-4.38M	-5.51M	-3.45M	-92K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	161.05M	174.1M	468.81M	196K
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	161.05M	174.1M	468.81M	0
Net Change in Cash	-	-	-	-
Free Cash Flow+	-161.05M	-174.1M	-197.7M	-128.64M
FCF Margin %	-	-	-	-
FCF Growth %	-	-0.08%	-0.14%	0.35%
FCF per Share	-9.65	-10.43	-11.85	-7.59
FCF Conversion (FCF/Net Income)	0.89x	0.89x	0.94x	1.00x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-171.33%	-63.57%
Return on Invested Capital (ROIC)	-1770.89%	-5378.8%	-5118.46%	-505.39%
Debt / Equity	-	-	0.06x	0.06x
FCF Conversion	0.89x	0.89x	0.94x	1.00x

Frequently Asked Questions

Growth & Financials

Mural Oncology plc (MURA) grew revenue by 0.0% over the past year. Growth has been modest.

Mural Oncology plc (MURA) reported a net loss of $119.1M for fiscal year 2024.

Dividend & Returns

Mural Oncology plc (MURA) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.

Mural Oncology plc (MURA) had negative free cash flow of $118.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener